home > Investment > The settled enterprises
Nanjing Merial Animal Health Co., Ltd.
Nanjing Merial Animal Health Co., Ltd. (Merial Nanjing) was founded in 1998 with a total investment of USD12.36 million and a registered capital of USD6.8 million, where Chinese and foreign equity holders contribute USD3.4 million, respectively. Covering an area of 6,501 square meters with a floor area of 3,090 square meters, it is a hi-tech joint venture invested by Merial Group (France) and CAHIC, which produces and sells quality poultry-oriented inactivated vaccines. As the No. 1 animal health company in the world, Merial is affiliated to the Sanofi Group, and has 16 prodution plants and 10 R&D centers across the globe. It invests as much as USD150 million in R&D activities and has extended its business to more than 150 countries worldwide. CAHIC is the largest animal vaccine producer in China, holding a key position in the domestic market. For the purpose of further optimizing resources, the Chinese equity holder of Merial Nanjing was changed at the end of 2011 into QYH Biotech Company Limited, which is concurrently under CAHG.

Located in Yuhua District, Nanjing with beautiful scenery, Merial Nanjing has been sticking to its only objective of "always satisfying consumer demands and providing every consumer with high-quality products and services" ever since its establishment. Realization of this objective is to be best ensured by the most advanced technologies and production equipment, the plants designed and built in conformity with the latest international standards and western management models of Merial Group, the world's largest animal vaccine producer.

As the only domestic vaccine producer that has achieved fully automatic and enclosed production, the company owns 6 world-class and nationally-leading production technologies, including the fully automatic inoculation and harvest technology, the cell suspension culture technology, the antigen concentration technology, the low-temperature emulsification technology, the fully-enclosed production system and automatic control technology. The advanced production technologies, processes and equipment as well as strict management enable Merial Nanjing to offer top poultry-oriented inactivated vaccine products to the international market. In 2011, the company reported an annual sales revenue of nearly RMB50 million, paid approximately RMB5 million of tax, and held a staff of 50 people.
Copyright 2009 Nanjing China All Rights Reserved 2013 Total visits:显示网站总访问量